Literature DB >> 32001388

Multiple predictively equivalent risk models for handling missing data at time of prediction: With an application in severe hypoglycemia risk prediction for type 2 diabetes.

Sisi Ma1, Pamela J Schreiner2, Elizabeth R Seaquist3, Mehmet Ugurbil4, Rachel Zmora2, Lisa S Chow5.   

Abstract

The presence of missing data at the time of prediction limits the application of risk models in clinical and research settings. Common ways of handling missing data at the time of prediction include measuring the missing value and employing statistical methods. Measuring missing value incurs additional cost, whereas previously reported statistical methods results in reduced performance compared to when all variables are measured. To tackle these challenges, we introduce a new strategy, the MMTOP algorithm (Multiple models for Missing values at Time Of Prediction), which does not require measuring additional data elements or data imputation. Specifically, at model construction time, the MMTOP constructs multiple predictively equivalent risk models utilizing different risk factor sets. The collection of models are stored and to be queried at prediction time. To predict an individual's risk in the presence of incomplete data, the MMTOP selects the risk model based on measurement availability for that individual from the collection of predictively equivalent models and makes the risk prediction with the selected model. We illustrate the MMTOP with severe hypoglycemia (SH) risk prediction based on data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. We identified 77 predictively equivalent models for SH with cross-validated c-index of 0.77 ± 0.03. These models are based on 77 distinct risk factor sets containing 12-17 risk factors. In terms of handling missing data at the time of prediction, the MMTOP outperforms all four tested competitor methods and maintains consistent performance as the number of missing variables increase.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Missing data; Risk factors; Risk modeling; T2DM

Mesh:

Year:  2020        PMID: 32001388      PMCID: PMC7088462          DOI: 10.1016/j.jbi.2020.103379

Source DB:  PubMed          Journal:  J Biomed Inform        ISSN: 1532-0464            Impact factor:   6.317


  31 in total

1.  Complexity in biological signaling systems.

Authors:  G Weng; U S Bhalla; R Iyengar
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

2.  From research to daily clinical practice: what are the challenges in "translation"?

Authors:  Chris Feifer; Judith Fifield; Steven Ornstein; Andrew S Karson; David Westfall Bates; Katherine R Jones; Perla A Vargas
Journal:  Jt Comm J Qual Saf       Date:  2004-05

3.  Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes.

Authors:  Stuart A Ross; Hugh D Tildesley; John Ashkenas
Journal:  Curr Med Res Opin       Date:  2011-09-23       Impact factor: 2.580

4.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

Review 5.  Hypoglycemia.

Authors:  Mazen Alsahli; John E Gerich
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12       Impact factor: 4.741

6.  Analysis and computational dissection of molecular signature multiplicity.

Authors:  Alexander Statnikov; Constantin F Aliferis
Journal:  PLoS Comput Biol       Date:  2010-05-20       Impact factor: 4.475

7.  Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.

Authors:  Hertzel C Gerstein; Michael E Miller; Faramarz Ismail-Beigi; Joe Largay; Charlotte McDonald; Heather A Lochnan; Gillian L Booth
Journal:  Lancet       Date:  2014-07-31       Impact factor: 79.321

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

Authors:  Michael E Miller; Denise E Bonds; Hertzel C Gerstein; Elizabeth R Seaquist; Richard M Bergenstal; Jorge Calles-Escandon; R Dale Childress; Timothy E Craven; Robert M Cuddihy; George Dailey; Mark N Feinglos; Farmarz Ismail-Beigi; Joe F Largay; Patrick J O'Connor; Terri Paul; Peter J Savage; Ulrich K Schubart; Ajay Sood; Saul Genuth
Journal:  BMJ       Date:  2010-01-08
View more
  2 in total

1.  A novel early diagnostic framework for chronic diseases with class imbalance.

Authors:  Xiaohan Yuan; Shuyu Chen; Chuan Sun; Lu Yuwen
Journal:  Sci Rep       Date:  2022-05-21       Impact factor: 4.996

2.  An Approach towards Increasing Prediction Accuracy for the Recovery of Missing IoT Data Based on the GRNN-SGTM Ensemble.

Authors:  Roman Tkachenko; Ivan Izonin; Natalia Kryvinska; Ivanna Dronyuk; Khrystyna Zub
Journal:  Sensors (Basel)       Date:  2020-05-04       Impact factor: 3.576

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.